Beam Therapeutics (BEAM) Strengthens Cash Position as Key Trials Move Forward

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best gene-editing stocks to buy according to hedge funds. On November 14, Beam Therapeutics Inc. (NASDAQ:BEAM) announced Q3 2025 results in which it reported wider losses than last year’s. The reported net loss was $112.7 million ($1.10/share), higher than $96.7 million ($1.17/share) for Q3 2024.

Management attributed the losses to increased research and development (R&D) expenses ($109.8 million vs. $94.3 million in Q3 2024). This also includes expenses for in-process R&D from recent acquisitions. Despite these losses, Beam ended the quarter with $1.1 billion in cash, cash equivalents, and marketable securities, up from $850.7 million at year-end 2024. This strong cash position gives the company a projected runway into 2028, enough to fund its major clinical programs, management stated.

The company also reported significant clinical progress. For instance, management noted that enrollment and dosing in the pivotal BEAM-302 Phase 1/2 study for alpha-1 antitrypsin deficiency are progressing well. This trial is the first clinical effort to directly correct a disease-causing mutation in vivo, and management emphasized its status as a top priority. The BEACON Phase 1/2 trial for BEAM-101 in sickle cell disease reached a milestone with its updated data being accepted for presentation at the December American Society of Hematology (ASH) meeting. And dosing has begun for BEAM-103, an anti-CD117 monoclonal antibody in a healthy volunteer trial.

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company. It develops precision genetic medicines using its proprietary base-editing technology. Its main products include investigational therapies such as BEAM-101 and BEAM-302.

READ NEXT: 10 Best European Bank Stocks to Buy Now and 11 Best Solar Energy Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.